Phase 3 Study: Venglustat Shows Promise for CNS Manifestations of Type 3 Gaucher Disease In a phase 3 study, venglustat showed superiority over ERT in treating neurological symptoms of type 3 Gaucher disease (GD).

Sanofi has announced that #Venglustat met the primary endpoint and 3 out of 4 secondary endpoints in the phase 3 study evaluating the once-daily oral therapy for patients with type 3 #GaucherDisease (GD).

Read more: https://bit.ly/3NVWSqC

#RareDisease #GD #MedSky